Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599787 | 0.83 | GAA (0.59) | KMT2AALDH1A1MAPK1LMNASMN1; SMN2 | |
| SCHEMBL3484826 | 0.83 | GAA (0.59) | KMT2AALDH1A1MAPK1LMNASMN1; SMN2 | |
| SCHEMBL18986533 | 0.83 | LMNA (0.55) | KMT2AALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL7673729 | 0.80 | ALDH1A1 (0.56) | L3MBTL1KMT2AALDH1A1MAPK1LMNA | |
| SCHEMBL8008989 | 0.80 | MCHR1 (0.60) | KMT2AALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL14002193 | 0.80 | MCHR1 (0.60) | KMT2AALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL9865284 | 0.77 | DNM1 (0.46) | L3MBTL1KMT2AALDH1A1MAPK1TDP1 | |
| SCHEMBL5800952 | 0.77 | L3MBTL1 (0.44) | L3MBTL1KMT2AALDH1A1MAPK1TDP1 | |
| SCHEMBL12169294 | 0.77 | LMNA (0.52) | KMT2ATDP1LMNASMN1; SMN2HTT | |
| SCHEMBL10463695 | 0.76 | CNR2 (0.49) | L3MBTL1KMT2AALDH1A1MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20100016229-A1 | Oral GLP-1 Formulations | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20100016229-A1 | Oral GLP-1 Formulations | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20100016229-A1 | Oral GLP-1 Formulations | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20060286129-A1 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| WO-2005062874-A2 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050147662-A1 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147662-A1 | Compounds and compositions for delivering active agents | SERPINB1, ELANE, MMP8 | L3MBTL1 3798/4885KMT2A 4537/4885ALDH1A1 2208/4885 |
| US-20060286129-A1 | Oral GLP-1 formulations | GLP1R, GIPR, GCGR | L3MBTL1 3877/4885KMT2A 3557/4885ALDH1A1 3278/4885 |
| US-20100016229-A1 | Oral GLP-1 Formulations | GLP1R, GIPR, GCGR | L3MBTL1 4068/4885KMT2A 3427/4885ALDH1A1 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.